The Immuno-Oncology (I-O) Core works directly with clinical investigators to design, execute, and analyze correlative studies to gain mechanistic insights into immuno-oncology clinical trials. The core provides unique services as well as works with other cores on resources that are already available at City of Hope.
Using the Facility
Basic Text Field
I-O Core-specific services include:
High-parameter (six-marker) multiplex immunofluorescence of formalin fixed tissue samples using a spectral imaging system (Akoya Ve<:tra 3.0). We provide quantitative spatial image analysis using machine-learning approaches for cell phenotyping and tissue segmentation, which enable cell density calculations and a variety of spatial interaction metrics.
High-parameter flow cytometry for complex immune subset proHing of dinical tissue samples. These assays utilize the Cytek Aurora spectral cytometer in the Analytical Cytornetry Core.
Expertise on study design, protocol development, proposal approval, experimental execution, sample management, research data generation, analysis and publication, and database and infonnatics for cancer immunotherapy dinical trials.
The Vectra 3 automated quantitative pathology imaging system provides multispectral and automated multi-slide imaging of up to six slides to detect and measure weakly expressed and overlapping biomarkers in H&E, IHC or IF intact FFPE tissue sections or TM
Peter P. Lee, M.D., is the chair of the Department of Immuno-Oncology at Beckman Research Institute of City of Hope and a beneficiary of The Christopher Family Endowed Innovation Fund for Alzheimer’s Disease and Breast Cancer Research in Honor of Vineta Christopher. He is co-leader of the Cancer Immunotherapeutics Program, professor in the Department of Hematology & Hematopoietic Cell Transplantation, and the Billy and Audrey L. Wilder Professor in Cancer Immunotherapeutics.